Now showing items 1-12 of 12

    • Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells 

      Suzuki, Rikio; Kikuchi, Shohei; Harada, Takeshi; Mimura, Naoya; Minami, Jiro; Ohguchi, Hiroto; Yoshida, Yasuhiro; Sagawa, Morihiko; Gorgun, Gullu; Cirstea, Diana; Cottini, Francesca; Jakubikova, Jana; Tai, Yu-Tzu; Chauhan, Dharminder; Richardson, Paul G.; Munshi, Nikhil; Ando, Kiyoshi; Utsugi, Teruhiro; Hideshima, Teru; Anderson, Kenneth C. (Public Library of Science, 2015)
      Heat shock protein (HSP)90 inhibitors have shown significant anti-tumor activities in preclinical settings in both solid and hematological tumors. We previously reported that the novel, orally available HSP90α/β inhibitor ...
    • Expanded Safety Experience with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma 

      Chen, Christine; Reece, Donna E; Niesvizky, Ruben; Boccia, Ralph V; Stadtmauer, Edward A; Abonour, Rafat; Matous, Jeffrey; Kumar, Shaji; Bahlis, Nizar J; Alsina, Melissa; Vescio, Robert; Coutre, Steven E; Pietronigro, Dennis; Knight, Robert D; Zeldis, Jerome B; Rajkumar, Vincent; Siegel, David; Richardson, Paul Gerard Guy (Blackwell Publishing Ltd, 2009)
      Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006. In April 2005, the FDA and patient ...
    • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma 

      Bolli, Niccolo; Avet-Loiseau, Hervé; Wedge, David C.; Van Loo, Peter; Alexandrov, Ludmil B.; Martincorena, Inigo; Dawson, Kevin J.; Iorio, Francesco; Nik-Zainal, Serena; Bignell, Graham R.; Hinton, Jonathan W.; Li, Yilong; Tubio, Jose M.C.; McLaren, Stuart; O' Meara, Sarah; Butler, Adam P.; Teague, Jon W.; Mudie, Laura; Anderson, Elizabeth; Rashid, Naim; Tai, Yu-Tzu; Shammas, Masood A.; Sperling, Adam S.; Fulciniti, Mariateresa; Richardson, Paul G.; Parmigiani, Giovanni; Magrangeas, Florence; Minvielle, Stephane; Moreau, Philippe; Attal, Michel; Facon, Thierry; Futreal, P Andrew; Anderson, Kenneth C.; Campbell, Peter J.; Munshi, Nikhil C. (Nature Pub. Group, 2014)
      Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number profiling and cytogenetics to analyse 84 myeloma ...
    • Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease 

      Dowling, Paul; Hayes, Catriona; Ting, Kay Reen; Hameed, Abdul; Meiller, Justine; Mitsiades, Constantine; Anderson, Kenneth C; Clynes, Martin; Clarke, Colin; Richardson, Paul; O’Gorman, Peter (BioMed Central, 2014)
      Background: Bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma ...
    • Lenalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma 

      Görgün, Güllü; Nijhof, Inger S; Raymakers, Reinier A; Lokhorst, Henk M; Groen, Richard W.j.; Jakubikova, Jana; Mitsiades, Constantine S; Hideshima, Teru; Laubach, Jacob; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl; van de Donk, Niels WCJ (Dove Medical Press, 2012)
      Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with ...
    • The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms 

      Richardson, Paul Gerard Guy; Laubach, Jacob; Schlossman, Robert Lawrence; Ghobrial, Irene; Mitsiades, Constantine S; Rosenblatt, Jacalyn Mara; Mahindra, Anuj; Raje, Noopur; Munshi, Nikhil C; Anderson, Kenneth Carl (Blackwell Publishing Ltd, 2011)
      Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related ...
    • A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients 

      Bae, Jooeun; Prabhala, Rao; Voskertchian, Annie; Brown, Andrew; Maguire, Craig; Richardson, Paul; Dranoff, Glen; Anderson, Kenneth C.; Munshi, Nikhil C. (2014)
      We evaluated a cocktail of HLA-A2-specific peptides including heteroclitic XBP1 US184-192 (YISPWILAV), heteroclitic XBP1 SP367-375 (YLFPQLISV), native CD138260-268 (GLVGLIFAV) and native CS1239-247 (SLFVLGLFL), for their ...
    • A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells 

      Das, Deepika Sharma; Ray, Arghya; Das, Abhishek; Song, Yan; Oronsky, Bryan; Richardson, Paul; Scicinski, Jan; Chauhan, Dharminder; Anderson, Kenneth C. (2016)
      The hypoxic bone-marrow (BM) microenvironment confers growth/survival and drug-resistance in multiple myeloma (MM) cells. Novel therapies targeting the MM cell in its hypoxic-BM milieu may overcome drug resistance. Recent ...
    • RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS 

      Cottini, Francesca; Hideshima, Teru; Xu, Chunxiao; Sattler, Martin; Dori, Martina; Agnelli, Luca; Hacken, Elisa ten; Bertilaccio, Maria Teresa; Antonini, Elena; Neri, Antonino; Ponzoni, Maurilio; Marcatti, Magda; Richardson, Paul G.; Carrasco, Ruben; Kimmelman, Alec C.; Wong, Kwok-Kin; Caligaris-Cappio, Federico; Blandino, Giovanni; Kuehl, W. Michael; Anderson, Kenneth C.; Tonon, Giovanni (2014)
      Oncogene–induced DNA damage elicits genomic instability in epithelial cancer cells, but apoptosis is blocked through inactivation of the tumor suppressor p53. In hematological cancers, the relevance of ongoing DNA damage ...
    • Retraction: Fatty Acid Synthase is a Novel Therapeutic Target in Multiple Myeloma 

      Okawa, Yutaka; Hideshima, Teru; Ikeda, Hiroshi; Raje, Noopur; Vallet, Sonia; Kiziltepe, Tanyel; Yasui, Hiroshi; Enatsu, Sotaro; Pozzi, Samantha; Breitkreutz, Iris; Cirstea, Diana; Santo, Loredana; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl (Blackwell Publishing Ltd, 2008)
      This study investigated the biological significance of the inhibition of fatty acid synthase (FAS) in multiple myeloma (MM) using the small molecule inhibitor Cerulenin. Cerulenin triggered growth inhibition in both MM ...
    • A Review of Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma 

      Hideshima, Teru; Raje, Noopur; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl (Dove Medical Press, 2008)
      Lenalidomide (also known as Revlimid®, CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity ...
    • Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma 

      Prabhala, Rao H.; Fulciniti, Mariateresa; Pelluru, Dheeraj; Rashid, Naim; Nigroiu, Andreea; Nanjappa, Puru; Pai, Christine; Lee, Saem; Prabhala, Nithya S.; Bandi, Rajya Lakshmi; Smith, Robert; Lazo-Kallanian, Suzan B.; Valet, Sonia; Raje, Noopur; Gold, Jason S.; Richardson, Paul G.; Daley, John F.; Anderson, Kenneth C.; Ettenberg, Seth A.; Di Padova, Franco; Munshi, Nikhil C. (2015)
      We have previously demonstrated that interleukin-17A (IL-17) producing Th17 cells are significantly elevated in blood and bone marrow (BM) in multiple myeloma (MM) and IL-17A promotes MM cell growth via the expression of ...